BridgeMD
Tests treatment safety and results for Craniopharyngiomas
Official title Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
ClinicalTrials.gov ID: NCT06970145
What this study is testing
What is Anlotinib?
Anlotinib is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for craniopharyngiomas.
Also referred to as Anlotinib Hydrochloride Capsules.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Primary Aim: To assess the objective remission rate (ORR) of patients with recurrent craniopharyngiomas treated with anlotinib . Secondary Aims: 1.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age 18-75 years old, regardless of gender
- recurrent craniopharyngioma (recurrence after total resection or regrowth of residual tumor) confirmed by pathology and imaging data
- predominantly cystic or solid recurrence of the tumor
- measurable lesions (according to the RECIST criteria)
- Karnofsky score ≥ 70, expected survival ≥ 3 months
You likely can't join if
- Have a combination of other intracranial tumors or severe brain lesions
- primary craniopharyngioma
- have severe uncontrolled heart, lung, kidney, or liver disease
- children, pregnant or breastfeeding women
- prior treatment with the same investigational drug
- active infections, including HIV, HBV, or HCV infections
See the full eligibility criteria
- Age 18-75 years old, regardless of gender
- recurrent craniopharyngioma (recurrence after total resection or regrowth of residual tumor) confirmed by pathology and imaging data
- predominantly cystic or solid recurrence of the tumor
- measurable lesions (according to the RECIST criteria)
- Karnofsky score ≥ 70, expected survival ≥ 3 months
- laboratory parameters (liver and kidney function, blood tests, etc.) within the normal range or under control
- signed informed consent and willing to participate in the study
- Have a combination of other intracranial tumors or severe brain lesions
- primary craniopharyngioma
- have severe uncontrolled heart, lung, kidney, or liver disease
- children, pregnant or breastfeeding women
- prior treatment with the same investigational drug
- active infections, including HIV, HBV, or HCV infections
- patients who do not meet the contraindications to the medication
- have a history of severe allergy to the investigational drug
- have psychiatric illnesses or cognitive impairments and unable to complete follow-up visits or understand the purpose of the study
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.